Eli Lilly and Company (NYSE:LLY) Holdings Lifted by Hutchens & Kramer Investment Management Group LLC

Hutchens & Kramer Investment Management Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 9.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,658 shares of the company's stock after purchasing an additional 1,225 shares during the quarter. Eli Lilly and Company comprises about 5.7% of Hutchens & Kramer Investment Management Group LLC's investment portfolio, making the stock its 3rd biggest position. Hutchens & Kramer Investment Management Group LLC's holdings in Eli Lilly and Company were worth $10,544,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Summit Financial Strategies Inc. raised its holdings in Eli Lilly and Company by 0.5% during the 3rd quarter. Summit Financial Strategies Inc. now owns 2,105 shares of the company's stock worth $1,865,000 after purchasing an additional 11 shares during the last quarter. Prio Wealth Limited Partnership increased its holdings in shares of Eli Lilly and Company by 0.5% in the third quarter. Prio Wealth Limited Partnership now owns 2,411 shares of the company's stock worth $2,136,000 after acquiring an additional 11 shares in the last quarter. First Community Trust NA lifted its stake in Eli Lilly and Company by 4.9% in the third quarter. First Community Trust NA now owns 257 shares of the company's stock valued at $228,000 after buying an additional 12 shares in the last quarter. Hummer Financial Advisory Services Inc raised its stake in shares of Eli Lilly and Company by 1.0% in the 3rd quarter. Hummer Financial Advisory Services Inc now owns 1,271 shares of the company's stock valued at $1,126,000 after purchasing an additional 12 shares during the period. Finally, James Hambro & Partners LLP boosted its position in shares of Eli Lilly and Company by 3.7% during the third quarter. James Hambro & Partners LLP now owns 340 shares of the company's stock worth $301,000 after buying an additional 12 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 2.4 %

Shares of NYSE:LLY traded up $19.51 during midday trading on Thursday, hitting $823.59. 2,641,960 shares of the stock were exchanged, compared to its average volume of 3,922,886. The business's 50-day moving average price is $780.80 and its 200 day moving average price is $845.98. Eli Lilly and Company has a 12 month low of $637.00 and a 12 month high of $972.53. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $781.85 billion, a price-to-earnings ratio of 89.04, a P/E/G ratio of 1.59 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. During the same quarter last year, the company posted $0.10 earnings per share. The company's revenue was up 20.4% compared to the same quarter last year. Analysts predict that Eli Lilly and Company will post 12.98 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has approved a share buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to buy up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company's dividend payout ratio is presently 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the sale, the chief accounting officer now owns 5,480 shares of the company's stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.13% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on LLY. Wells Fargo & Company decreased their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an "overweight" rating for the company in a research note on Tuesday. Barclays reduced their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an "overweight" rating for the company in a report on Thursday, October 31st. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a "buy" rating on the stock in a research note on Monday, November 4th. Redburn Atlantic raised shares of Eli Lilly and Company to a "hold" rating in a report on Monday, November 4th. Finally, Sanford C. Bernstein began coverage on Eli Lilly and Company in a report on Thursday, October 17th. They issued an "outperform" rating and a $1,100.00 price objective on the stock. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $997.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.